Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Claudio, Catalani"'
Autor:
Erika Terzuoli, Stefania Meini, Paola Cucchi, Claudio Catalani, Cecilia Cialdai, Carlo Alberto Maggi, Antonio Giachetti, Marina Ziche, Sandra Donnini
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e84358 (2014)
Bradykinin (BK) induces angiogenesis by promoting vessel permeability, growth and remodeling. This study aimed to demonstrate that the B2R antagonist, fasitibant, inhibits the BK pro-angiogenic effects.We assesed the ability of fasibitant to antagoni
Externí odkaz:
https://doaj.org/article/db8eba0e43004b1c94d91555623eca59
Autor:
Mauro Galeazzi, Laura Tinti, Claudio Catalani, Antonella Fioravanti, Claudio Valenti, C.A. Maggi, Stefania Meini, Paola Cucchi, Francesca Bellucci, S. Niccolini
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 385:777-786
This study investigates the effect of the selective and potent B2 receptor antagonist fasitibant (MEN16132) on the proinflammatory effect of bradykinin (BK) and its interaction with interleukin 1β (IL-1β) in human synoviocytes. PGE2 content was det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab026bbf2dc65fe0c4f2c6a51c10dfc
https://doi.org/10.1007/s00210-012-0762-y
https://doi.org/10.1007/s00210-012-0762-y
Autor:
C.A. Maggi, Laura Quartara, Paola Cucchi, Luigi Rotondaro, Sandro Giuliani, Alessandro Giolitti, Francesca Bellucci, Sabrina Zappitelli, Claudio Catalani, Stefania Meini
Publikováno v:
British Journal of Pharmacology. 162:1202-1212
BACKGROUND AND PURPOSE Icatibant is a well-known kinin B2 receptor antagonist currently used for angiooedema attacks. MEN16132 is a non-peptide B2 receptor antagonist, more potent and long lasting than icatibant in different models. Here we studied t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f5c166200d1c2ee03a8ade20b775f0e
https://doi.org/10.1111/j.1476-5381.2010.01133.x
https://doi.org/10.1111/j.1476-5381.2010.01133.x
Autor:
Sandro Giuliani, C.A. Maggi, Francesca Bellucci, Stefania Meini, Paola Cucchi, Claudio Catalani
Publikováno v:
British Journal of Pharmacology. 162:611-622
BACKGROUND AND PURPOSE In osteoarthritis (OA), bradykinin (BK) is known to contribute to pain and synovitis, but not to cartilage degradation. Here, we investigated effects of BK and its antagonists on chondrocytes, cells involved in cartilage homeos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6199ae4795c9509f0fea51296dc1dae
https://doi.org/10.1111/j.1476-5381.2010.01062.x
https://doi.org/10.1111/j.1476-5381.2010.01062.x
Autor:
Claudio Catalani, Stefania Meini, Paola Cucchi, Sandro Giuliani, Francesca Bellucci, C.A. Maggi
Publikováno v:
British Journal of Pharmacology. 158:1996-2004
Background and purpose: Bradykinin (BK) and B2 receptors have been implicated in the pathophysiology of osteoarthritis (OA), and synovitis is one of its hallmarks. Here, the selective B2 receptor antagonists MEN16132 and icatibant have been pharmacol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f84c9a974a612dc8eec53622f48ee52
https://doi.org/10.1111/j.1476-5381.2009.00511.x
https://doi.org/10.1111/j.1476-5381.2009.00511.x
Autor:
Sandro Giuliani, Francesca Bellucci, Paolo Santicioli, Stefania Meini, Alessandro Giolitti, Claudio Catalani, Paola Cucchi
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 329:486-495
Ibodutant (MEN15596, [1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) is a tachykinin NK(2) receptor (NK(2)R) antagonist currently under phase II clinical trials for irritable bowel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bc0f82ced491c29087795044a1c95a2
https://doi.org/10.1124/jpet.108.150201
https://doi.org/10.1124/jpet.108.150201
Autor:
Claudio Catalani, Sandro Giuliani, Francesca Bellucci, Paola Cucchi, Stefania Meini, C.A. Maggi, Paolo Santicioli
Publikováno v:
British Journal of Pharmacology. 150:313-320
Background and purpose: The aim was to characterize the recently discovered non-peptide antagonist MEN16132 at the mouse B2 receptor, relative to other antagonists. Experimental approach: [3H]-BK binding experiments used mouse lung and ileum tissue m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22d025be31eb945fbc17b3bec1d16f95
https://doi.org/10.1038/sj.bjp.0706995
https://doi.org/10.1038/sj.bjp.0706995
Autor:
Claudio Catalani, Claudio Valenti, Cecilia Cialdai, Carlo Alberto Maggi, Manuela Tramontana, Stefania Meini, Sandro Giuliani, Rose-Marie Catalioto, Maria Altamura, Alessandro Lecci, Riccardo Patacchini
Publikováno v:
European Journal of Pharmacology. 549:140-148
The pharmacological profile of MEN15596 or (6-methyl-benzo[b]thiophene-2-carboxylic acid [1-(2-phenyl-1R-{[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl}-ethylcarbamoyl)-cyclopentyl]-amide), a novel potent and selective tachykinin NK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f17d2708205033e104545cc7287ef8c2
https://doi.org/10.1016/j.ejphar.2006.08.021
https://doi.org/10.1016/j.ejphar.2006.08.021
Autor:
Maria Altamura, Antonio Guidi, Paola Cucchi, Carlo Alberto Maggi, Alessandro Giolitti, Claudio Catalani, Luigi Rotondaro, Franco Pasqui, Stefania Meini, Sabrina Zappitelli, Sandro Giuliani, Francesca Bellucci
Publikováno v:
European Journal of Pharmacology. 516:104-111
The pharmacological outline of a novel and original antagonist at the human tachykinin NK 2 receptor is presented, namely MEN13510 ( N - N ′-bis-[2-(1 H -indol-3-yl)-ethyl]- N , N ′-bis-(3-thiomorpholin-4-yl-propyl)-phthalamide). MEN13510 retaine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc34690a2ecc91033cda238a0c124076
https://doi.org/10.1016/j.ejphar.2005.04.033
https://doi.org/10.1016/j.ejphar.2005.04.033
Autor:
Luigi Rotondaro, Carlo Alberto Maggi, Stefania Meini, Rose-Marie Catalioto, Alessandro Giolitti, Sandro Giuliani, Angela Faiella, Francesca Bellucci, Laura Quartara, Claudio Catalani, Francisco M. Pinto, María L. Candenas
Publikováno v:
European Journal of Pharmacology. 499:229-238
In the present study, we have investigated, by binding and functional experiments, the pharmacological profile of a new human tachykinin NK(2) receptor splice variant named beta isoform. Neurokinin A, nepadutant, SR48968 [(S)-N-methyl-N[4-(4-acetylam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c10f73eae43ac02496cc15d543b37d0
https://doi.org/10.1016/j.ejphar.2004.07.075
https://doi.org/10.1016/j.ejphar.2004.07.075